{"id":464910,"date":"2021-03-25T07:08:07","date_gmt":"2021-03-25T11:08:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464910"},"modified":"2021-03-25T07:08:07","modified_gmt":"2021-03-25T11:08:07","slug":"hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/","title":{"rendered":"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper"},"content":{"rendered":"

<\/p>\n

HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper<\/b><\/p>\n

DENVER–(BUSINESS WIRE<\/a>)–
\nHempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO)<\/b> (\u201cHempFusion<\/b>\u201d or the \u201cCompany<\/b>\u201d), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce it has completed, in collaboration with the Inflammatory Markers Laboratory (\u201cIML<\/b>\u201d) located in Wichita, Kansas, a pilot study that assessed the effect of the HempFusion formulation CBD Capsules\u00ae (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test (which measures urinary 11-dehydro thromboxane B2, the stable end product of intracellular thromboxane metabolism that has been shown to correlate with inflammation) and has released a white paper titled \u201cOral Formulation May Modulate Thromboxane Production<\/i>\u201di<\/sup>.\n<\/p>\n

\nResults of the pilot study have shown potential promise in the area of inflammatory markers and possible effects on exaggerated inflammation.\n<\/p>\n

\n\u201cOur laboratory has demonstrated the effectiveness of numerous products in reducing thromboxane production,\u201d commented Gordon Ens, Director of IML. \u201cI was pleased to see a CBD product show such a significant reduction of thromboxane in this pilot trial.\u201d\n<\/p>\n

\nThe white paper, expected to be published shortly, is co-authored by Gordon Ens, Director of IML and George Fritsma, Professor at University of Alabama, and illustrates the potential of tracking and elucidating biomarkers sensitive to inflammation in addition to how novel compounds and formulas modulate the expression of these markers.\n<\/p>\n

\nJason Mitchell, N.D., HempFusion\u2019s Co-Founder and Chief Executive Officer commented, \u201cWe are committed to furthering research in the area of hemp-derived CBD and this pilot trial and soon to be published white paper reinforces our continued focus on the safe and effective use of hemp-derived CBD products.\u201d\n<\/p>\n

\nHempFusion is dedicated to research related to toxicology safety, which is evident through its involvement and co-sponsoring of the ValidCare Human Observational Safety Study, what is believed to be the largest CBD toxicology study of its kind ever completed to date. HempFusion continues to focus on research & development, pilot studies, and clinical trials, to advance the science of CBD.\n<\/p>\n

ABOUT HEMPFUSION<\/b><\/p>\n

\nHempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion\u2019s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor\/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion\u2019s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion\u2019s CBD products are based on a proprietary Whole Food Hemp Complex\u2122 and are available in-store or by visiting HempFusion online at www.hempfusion.com<\/a> or www.probulin.com<\/a>.\n<\/p>\n

\nFollow HempFusion on Twitter<\/a>, Facebook<\/a> and Instagram<\/a> and Probulin on Twitter<\/a>, Facebook<\/a> and Instagram<\/a>.\n<\/p>\n

FORWARD-LOOKING STATEMENTS<\/b><\/p>\n

\nThis news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, \u201cforward-looking statements<\/b>\u201c) that relate to HempFusion\u2019s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as \u201cwill likely result\u201d, \u201care expected to\u201d, \u201cexpects\u201d, \u201cwill continue\u201d, \u201cis anticipated\u201d, \u201canticipates\u201d, \u201cbelieves\u201d, \u201cestimated\u201d, \u201cintends\u201d, \u201cplans\u201d, \u201cforecast\u201d, \u201cprojection\u201d, \u201cstrategy\u201d, \u201cobjective\u201d and \u201coutlook\u201d) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the publication of the white paper and the Company\u2019s plans, focus and objectives.\n<\/p>\n

\nForward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion\u2019s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under \u201cForward-Looking Statements<\/i>\u201d and \u201cRisk Factors<\/i>\u201d in the final long form prospectus of the Company dated December 17, 2020 and available under the Company\u2019s profile on SEDAR at www.sedar.com<\/a>. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.\n<\/p>\n

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.<\/b><\/p>\n

\n__________________________\n<\/p>\n

i<\/sup> Oral Formulation May Modulate Thromboxane Production Gordon E. Ens, BA, MT(ASCP)1<\/sup>, George A. Fritsma, MS, MLS2<\/sup>, Elaina Goldsmith, DVM1<\/sup>, Victoria J. Heimerman, MT(ASCP)1
\n
1<\/sup>Inflammatory Markers Laboratory, Wichita, KS
\n
2<\/sup>University of Alabama at Birmingham, Birmingham, AL\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210325005299\/en\/<\/a><\/span><\/p>\n

\nJason Mitchell, N.D.
\n
Chief Executive Officer and Director
\n
Email: ir@hempfusion.com
\n<\/a>
Phone: 416-803-5638\n<\/p>\n

KEYWORDS:<\/b> Colorado United States North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Fitness & Nutrition Tobacco Specialty Food\/Beverage Alternative Medicine Health Cosmetics Retail Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper DENVER–(BUSINESS WIRE)– HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO) (\u201cHempFusion\u201d or the \u201cCompany\u201d), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce it has completed, in collaboration with the Inflammatory Markers Laboratory (\u201cIML\u201d) located in Wichita, Kansas, a pilot study that assessed the effect of the HempFusion formulation CBD Capsules\u00ae (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test (which measures urinary 11-dehydro thromboxane B2, the stable end product of intracellular thromboxane metabolism that has been shown to correlate with inflammation) and has released a white paper titled … <\/p>\n

Continue reading “HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464910","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper DENVER–(BUSINESS WIRE)– HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO) (\u201cHempFusion\u201d or the \u201cCompany\u201d), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce it has completed, in collaboration with the Inflammatory Markers Laboratory (\u201cIML\u201d) located in Wichita, Kansas, a pilot study that assessed the effect of the HempFusion formulation CBD Capsules\u00ae (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test (which measures urinary 11-dehydro thromboxane B2, the stable end product of intracellular thromboxane metabolism that has been shown to correlate with inflammation) and has released a white paper titled … Continue reading "HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-25T11:08:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper\",\"datePublished\":\"2021-03-25T11:08:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/\"},\"wordCount\":1039,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/\",\"name\":\"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-03-25T11:08:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/","og_locale":"en_US","og_type":"article","og_title":"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper - Market Newsdesk","og_description":"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper DENVER–(BUSINESS WIRE)– HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO) (\u201cHempFusion\u201d or the \u201cCompany\u201d), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce it has completed, in collaboration with the Inflammatory Markers Laboratory (\u201cIML\u201d) located in Wichita, Kansas, a pilot study that assessed the effect of the HempFusion formulation CBD Capsules\u00ae (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test (which measures urinary 11-dehydro thromboxane B2, the stable end product of intracellular thromboxane metabolism that has been shown to correlate with inflammation) and has released a white paper titled … Continue reading \"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-25T11:08:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper","datePublished":"2021-03-25T11:08:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/"},"wordCount":1039,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/","name":"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-03-25T11:08:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210325005299r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hempfusion-completes-inflammatory-markers-pilot-trial-releases-white-paper\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HempFusion Completes Inflammatory Markers Pilot Trial, Releases White Paper"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464910"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464910\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}